New bis-thiazolium analogues as potential antimalarial agents: design, synthesis, and biological evaluation. 2013

Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 CNRS-UM1&2, Université Montpellier 2, cc 1705, place E. Bataillon, 34095 Montpellier, France.

Bis-thiazolium salts are able to inhibit phosphatidylcholine biosynthesis in Plasmodium and to block parasite proliferation in the low nanomolar range. However, due to their physicochemical properties (i.e., permanent cationic charges, the flexibility, and lipophilic character of the alkyl chain), the oral bioavailability of these compounds is low. New series of bis-thiazolium-based drugs have been designed to overcome this drawback. They feature linker rigidification via the introduction of aromatic rings and/or a decrease in the overall lipophilicity through the introduction of heteroatoms. On the basis of the structure-activity relationships, a few of the promising compounds (9, 10, and 11) were found to exhibit potent antimalarial in vitro and in vivo activities (EC(50) < 10 nM and ED(50) ip < 0.7 mg/kg).

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D021241 Spectrometry, Mass, Electrospray Ionization A mass spectrometry technique used for analysis of nonvolatile compounds such as proteins and macromolecules. The technique involves preparing electrically charged droplets from analyte molecules dissolved in solvent. The electrically charged droplets enter a vacuum chamber where the solvent is evaporated. Evaporation of solvent reduces the droplet size, thereby increasing the coulombic repulsion within the droplet. As the charged droplets get smaller, the excess charge within them causes them to disintegrate and release analyte molecules. The volatilized analyte molecules are then analyzed by mass spectrometry. ESI Mass Spectrometry,Electrospray Ionization Mass Spectrometry,Mass Spectrometry, ESI,Spectrometry, ESI Mass

Related Publications

Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
July 2010, ChemMedChem,
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
May 2024, Bioorganic & medicinal chemistry letters,
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
July 2009, Bioorganic & medicinal chemistry,
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
July 2016, Molecules (Basel, Switzerland),
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
April 2006, Bioorganic & medicinal chemistry letters,
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
September 2001, Journal of medicinal chemistry,
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
April 2017, Archiv der Pharmazie,
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
July 2023, Molecules (Basel, Switzerland),
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
July 2019, European journal of medicinal chemistry,
Sergio A Caldarelli, and Siham El Fangour, and Sharon Wein, and Christophe Tran van Ba, and Christian Périgaud, and Alain Pellet, and Henri J Vial, and Suzanne Peyrottes
March 2020, European journal of medicinal chemistry,
Copied contents to your clipboard!